January 11, 2022 -- Takeda Pharmaceutical announced it is exercising its option to acquire Adaptate Biotherapeutics. Takeda will obtain Adaptate's antibody-based variable delta 1 gamma delta T-cell engager platform, as well as its preclinical candidate and discovery pipeline programs.
The planned acquisition complements Takeda's ongoing efforts to research and develop cell engagers for solid tumor applications, bolstered by the novel T-cell engager Cobra platform, which was acquired from Maverick Therapeutics, Takeda said. The acquisition follows Takeda's recently exercised option to acquire GammaDelta Therapeutics.
Adaptate was formed in 2019 as a spinout company from GammaDelta, with investment from Abingworth and Takeda, in which Takeda received an exclusive right to purchase Adaptate for a prenegotiated upfront payment. The acquisitions of Adaptate and GammaDelta are expected to be finalized in the first quarter of Takeda's fiscal year 2022, pending review under applicable antitrust laws.
Financial details of the acquisition were not disclosed.